IGM Biosciences Inc Ordinary Shares IGMS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay
-
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
-
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
-
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $14.50
- Day Range
- $13.25–14.94
- 52-Week Range
- $3.81–22.50
- Bid/Ask
- $12.22 / $15.35
- Market Cap
- $854.19 Mil
- Volume/Avg
- 101 / 345,680
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 297.05
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 204
- Website
- https://www.igmbio.com
Comparables
Valuation
|
Metric
|
IGMS
|
ANAB
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.97 | 97.20 | 3.83 |
Price/Sales | 297.05 | 30.80 | 5.57 |
Price/Cash Flow | — | — | — |
Price/Earnings
IGMS
ANAB
MGNX
Financial Strength
|
Metric
|
IGMS
|
ANAB
|
MGNX
|
|---|---|---|---|
Quick Ratio | 6.81 | 8.90 | 2.53 |
Current Ratio | 7.06 | 9.09 | 2.71 |
Interest Coverage | — | −6.09 | −128.87 |
Quick Ratio
IGMS
ANAB
MGNX
Profitability
|
Metric
|
IGMS
|
ANAB
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −45.61% | −30.08% | −59.21% |
Return on Equity (Normalized) | −95.44% | −166.16% | −120.96% |
Return on Invested Capital (Normalized) | −84.94% | −130.73% | −102.88% |
Return on Assets
IGMS
ANAB
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vvjpqdxwfb | Yjdpn | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hfssfbpn | Trwklz | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qskhmtgn | Mvwwgl | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qympzqgpj | Fdzfl | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Nhbzvfgq | Sktt | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Wsrsfcdm | Htxm | $28.3 Bil | |||
| Moderna Inc
MRNA
| Dngqqrfr | Xjlsy | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Slrwklvjf | Vmpk | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vdjbcywqb | Yyqlq | $13.3 Bil | |||
| Incyte Corp
INCY
| Zkhknqdz | Qymqxc | $13.0 Bil |
United States